Experimental Therapy with 9-[2-(Phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP): Origin of Resistance Cited by

Fol. Biol. 2007, 53, 79-84

https://doi.org/10.14712/fb2007053030079

Experimental Therapy with 9-[2-(Phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP): Origin of Resistance

Michal Zápotocký^1,2, J. Hanzalová², J. Starková¹, I. Votruba³, A. Holý³, Berta Otová²

¹Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
²Institute of Biology and Medical Genetics, 1st Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic
³Centre for New Antivirals and Antineoplastics, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Received February 2007
Accepted April 2007

Crossref Cited-by Linking

Gómez\u2010Coca Raquel B., Blindauer Claudia A., Sigel Astrid, Operschall Bert P., Holý Antonín, Sigel Helmut: Extent of Intramolecular \u03c0\u2010Stacks in Aqueous Solution in Mixed\u2010Ligand Copper(II) Complexes Formed by Heteroaromatic Amines and Several 2\u2010Aminopurine Derivatives of the Antivirally Active Nucleotide Analog 9\u2010[2\u2010(Phosphonomethoxy)ethyl]adenine (PMEA). Chemistry & Biodiversity 2012, 9, 2008. <https://doi.org/10.1002/cbdv.201200022>
Mertlíková-Kaiserová Helena, Rumlová Michaela, Tlou\u0161\u0165ová Eva, Procházková Eli\u0161ka, Holý Antonín, Votruba Ivan: Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG. Biochemical Pharmacology 2011, 82, 131. <https://doi.org/10.1016/j.bcp.2011.04.002>